Jung Won Shin
@scripjungwon
Senior Editor of Scrip Intelligence/The Pink Sheet @PharmaScrip @PharmaPinkSheet All views are mine.
ID: 1506430776598200320
23-03-2022 00:42:18
1,1K Tweet
56 Takipçi
60 Takip Edilen
Aside from multiple sizable global out-licensing deals, Korean bioventures saw a cancellation of other alliances, updated their pipelines and reported clinical trial progress in 2Q, while domestic IPO sentiment also improved, reports Scrip, Citeline Commercial. insights.citeline.com/scrip/focus-on…